Effects of PARP Inhibitor on Tumor Microenvironment in High-risk Endometrial Cancer Patients

Sponsor
The University of Hong Kong
Study ID
NCT05320757
Phase
EARLY_PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This is a window study where treatment-naïve patients will receive olaparib before definitive treatment. The aim is to evaluate the DNA damage and inflammatory response after PARP inhibitor.

Key Dates

Start date
Apr 1, 2022
Status verified
Jun 2025
Primary completion
May 31, 2025
Completion
May 31, 2025

Study Design

Enrollment
20 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Olaparib
    Olaparib: 300mg BID orally for 10 - 28 days (stop 3 - 4 days before definitive treatment)

Primary Outcome Measure

Extent of DNA damage [ Time Frame: Up to 18 months ]

Related Studies